Tag
This article analyzes global liver transplantation disparities relative to cirrhosis and chronic liver disease burden, revealing unequal access dominated by high-income countries and highlighting the role of health system development in tra
This study demonstrates that nucleos(t)ide analogue therapy significantly reduces cirrhosis and hepatocellular carcinoma risk in specific HBeAg-positive chronic HBV infection phases beyond current EASL 2025 treatment indications.
This multinational study reveals that specific gut microbiome profiles significantly correlate with 90-day hospitalisation risk in cirrhosis, enhancing prognostic accuracy beyond clinical features alone.
This study analyzes the epidemiology, treatment processes, and outcomes of critically ill cirrhosis patients undergoing continuous renal replacement therapy, highlighting high mortality rates, anticoagulation practices, and implications of
This review assesses the clinical utility of steatotic liver disease risk scores in predicting cirrhosis and hepatocellular carcinoma, highlighting the superior performance of the SAFE score for cirrhosis and challenges in HCC risk predicti
The LiveSMART trial demonstrates that lactulose, with or without sequential TeleTai-Chi, significantly reduces fall risk and related harms in cirrhotic patients without prior overt hepatic encephalopathy.
This study elucidates how intestinal blood vessel-associated macrophage dysfunction contributes to gut-vascular barrier breakdown and bacterial translocation in cirrhosis, revealing novel mechanisms that underlie systemic infection risks in
Carvedilol demonstrates superior effectiveness over nadolol and propranolol in reducing portal hypertension and preventing cirrhosis decompensation events, with emerging evidence supporting its preferential use in both compensated and decom
Cirrhosis entwined with diabetes presents unique clinical challenges. This article offers a pragmatic framework for diagnosis, tailored therapies, and multidisciplinary care to enhance outcomes across liver disease stages.
Rapid skeletal muscle loss occurs in a significant subset of cirrhosis patients and independently predicts waitlist mortality, highlighting sarcopenia as a critical therapeutic target in liver disease management.
A new organ failure score, A-TANGO, improves ACLF diagnosis and risk stratification compared to standard CLIF-C criteria, validated in large international cohorts.
Combining circulating methylated SEPT9 with alpha-fetoprotein significantly enhances early hepatocellular carcinoma detection in cirrhotic patients, outperforming AFP alone and allowing improved surveillance sensitivity and specificity.
In NA-treated cirrhotic chronic hepatitis B with complete viral suppression, HBsAg seroclearance was linked to lower HCC risk but not lower hepatic decompensation, reinforcing functional cure as a meaningful but incomplete clinical endpoint
A major 2026 cluster randomized trial shows that palliative care delivered by trained hepatologists is noninferior to specialist palliative care for improving quality of life in end-stage liver disease, supporting scalable integrated models
In a large international prospective cohort of hospitalized patients with cirrhosis, chronic kidney disease was common, clustered with metabolic risk, and strongly associated with acute kidney injury, more decompensation, and higher in-hosp
This review synthesizes clinical evidence for Belapectin, a Galectin-3 inhibitor, focusing on its ability to prevent esophageal varices in patients with MASH cirrhosis and portal hypertension as demonstrated in the NAVIGATE trial.
A prospective trial found that non-contrast abbreviated MRI detected hepatocellular carcinoma in cirrhotic patients far better than ultrasound, with most MRI-detected tumors found at an early, potentially curable stage.
The Translational Liver Cancer Consortium proposes a structured framework for developing and validating risk models to optimize HCC surveillance, addressing gaps in current clinical guidelines.
This review synthesizes large-scale cohort data defining specific spleen length and volume thresholds that significantly increase the 5-year absolute risk of hematologic cancers and chronic liver disease.
A 2025 bayesian meta-analysis of 14 RCTs (n=1,322) found shorter or no antibiotic prophylaxis after upper GI bleeding in cirrhosis was highly likely to be noninferior for mortality, though it increased reported bacterial infections. Study l
